Member Info for Miggy007

Seems a little unfair to say Dexamethasone is the only drug to bring down the mortality rate as Interferon Beta for all they know stops people getting to the latter severe stages, therefore bringing down the consequential mortality rate. Dex cannot be given early doors unlike SNG001, as Fauci stated would appear to make people worse.

Would love to have the data from the home trial to support what we already believe that this treatment is even more effective when administered early in the virus cycle.

That Jon Rahm shot across the water and then holing it was something else. Never seen anything like it.

David- yes that’s a good question. Heard several professors commenting on the Pfizer prelim result specifically asking that question, namely how did the vulnerable elderly patients fair in the trial. That data isn’t known yet or at least hasn’t been made public. They said they would like confirmation it works for that group too as that is the obvious goal here, a vaccine that works for the people most likely to die from COVID.

I think RM himself said ‘time is the enemy.’ Even if SNG isn’t in pole position for COVID this year it should still prove to be an essential therapeutic against it next year and many other respiratory viruses to come. Selling has been overdone imo. It seems a lot of PI’s have viewed the vaccine news as a black and white result good for them/bad for us. To me that’s incorrect and I’m willing to invest on it. Will be buying more tomorrow sub £1 if possible.

So why are you here if you’ve cashed in? Why not move on and afflict another board. :)

Parsley- talking of muppets who can’t read. You must be so use to misquoting people by now. RM never said ‘SNG is COVID’. He did say everything was about COVID, and it still is. SNG will still hopefully play a major role. If you don’t believe that why are you here?. You’re like a parasite really. Feeding off negativity. Well good luck with that bell end.

I think many have taken the vaccine news as a winner takes all scenario. The reality is no one vaccine will save the world and we will always need therapeutics for this and other respiratory viruses to come. What is this worth as a stockpiled general anti viral?. The recent raise as mentioned brought in 80million of value. Current market cap is around £200m. SP is low at that MC.

It was great headline news today but my main concern would be how long do the antibodies created by this vaccine last for?. Trial started in July and we know the inoculation process is given in two parts, three weeks apart, with about a month needed before someone’s deemed to have protection from the virus. So much of the trial study would have been walking around for six weeks or less. That to me isn’t enough time to know if antibodies will last 3 months or more. Evidence so far is that they drop off after 3 months or so. Throw in the mink strain of the virus which is more difficult for the immune system to recognise and therefore release antibodies due to subtle changes to the spike protein which the vaccines thus far concentrate on neutralising. Still a lot to prove in my opinion.

Super-Al, you certainly weren’t alone in struggling to contact the broker. I’d love to know who got the 80p buys. I tried on multiple platforms but couldn’t get through. Also tried to buy Novacyt when it hit 550p but couldn’t deal their either. Most annoying.

Probably in your other stocks Pete. Your 4K here pre 20th July would be worth about 20k now. All about the entry point old boy.

I don’t quite see if the Gov is that confident of getting the R down within a month why they are extending Furlough payments to March?. Something doesn’t add up.

I'm certain BOJO spealt out SNG SOS using morse code with his eyebrow movement. He couldnt say it obvs because we are all hush hush, but he did. It beats 'Broadsword to Dannyboy' :)

I was buying from 17p down and last buy at 14.5p. difficult to try catch a falling knife but ultimately the market cap here is £21million at close SP. I don't believe thats much for a company with this potential. I always thought profit taking combined with MM's grabbing some of the limited free float would make this drop rapid but i'm happy to hold so not concerned. A CE Mark normally adds 25% to a share value too so how low can this go before it becomes the bargain of the century.

the odds of SNG proceeding from phase II purely based on other phase II trials was around 20% through to bringing drug to market, we nailed that baby. That now increases to around 60-70% to get past phase III I believe, and possibly higher if you are confident of the science and the management team. Which I have always been.

Hi Vol :) it wasn't dodgy maths honest! the percentages came out of the reason phase III's fail not as an overall percentge. Anyways its hard to get a grip on it. But look at it worse ways as i did when we were 35p and tried to explain to Nolupus. The upside even if we are a coin toss 50-50 is huge here. Well worth the risk imho.

Think im right in saying that most trials fail at phase II level. Once you have efficacy and safety should hopefully be a case of just proving it in a bigger cohort. Broker put chance of success at Phase III at 70% which from what i have learnt is slightly above the average but those aren't bad odds. But i believe we can mark our's up a little. Reason for that is that 17% of phase III'S fail due to safety and 22% due to lack of funding and I don't see those factors as an issue in the case of SNG.

Apologies if already posted by this piece from today states the home trial data is due next, pilot part of trial, 120 patients dosed as we already know. . Assuming the Pivotal phase has been included in the reckoning here from a timeline perspective.

https://www.evaluate.com/vantage/articles/analysis/spotlight/scanning-horizon-future-covid-19-treatments

The trial findings that Dummy has intentionally missed out:

Key findings:
The odds of developing severe disease (e.g. requiring ventilation or resulting in death) during the treatment period (day 1 to day 16) were significantly reduced by 79% for patients receiving SNG001 compared to patients who received placebo (OR 0.21 [95% CI 0.04-0.97]; p=0.046).

Patients who received SNG001 were more than twice as likely to recover (defined as 'no limitation of activities' or 'no clinical or virological evidence of infection') over the course of the treatment period compared to those receiving placebo (HR 2.19 [95% CI 1.03-4.69]; p=0.043).

Over the treatment period, the measure of breathlessness was markedly reduced in patients who received SNG001 compared to those receiving placebo (p=0.007).

Three subjects (6%) died after being randomised to placebo. There were no deaths among subjects treated with SNG001.

Looks like Dumb wins the award for trying to buy back in at a cheaper price. Definately got his timing wrong on selling out. Good.

I think back then we all kept each other going tbh. I’m sure we all had moments of are we doing the right thing, am I mad?:). Been a bit off track tonight but some of the lessons you learn along the way (we are always learning I know) can hopefully save or make some people money. I would say too that if you don’t love doing research you probably shouldn’t risk your money on any form of investing. Probably best just chuck some money into a tracker fund and get busy with other things. GLA